Matinas Biopharma
- Founded: 2011
- Location: Bedminster, NJ
- Employee range: 11 - 50
- Clinical stage: Clin2 (fast track)
- Therapy area: Fungal infections (ODD)
- Drug types: INF
- Lead product: MAT2203
- Product link: https://www.matinasbiopharma.com/lnc-technology/lnc-platform
- Funding: 10-100M
matinasbiopharma.com linkedin.com job board
Short description:
Dyslipidemia treatments
Drug notes:
MAT2501 Clin1 non-tuberculous mycobacterium infections (ODD)
Long description:
Matinas Biopharma is improving the delivery method for nucleic acid therapeutics. Using their lipid nano-crystal (LNC) platform, Matinas is developing safe, intracellular, orally-administered delivery of a broad range of drug therapies, including small molecules, nucleic acid polymers, proteins, vaccines and gene editing technologies. LNCs are formulated as natural highly efficient spiral crystal, or “cochleate”, which encapsulates and protects drugs from harsh environments and releases them following fusion with the cell membrane. Matinas’ lead candidate, MAT2203, is an encochleated form of amphotericin B, an antifungal drug which is being tested for the treatment of invasive candidiasis and aspergillosis.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com